RENDLIZEP Trademark

Trademark Overview

On Friday, August 12, 2016, a trademark application was filed for RENDLIZEP with the United States Patent and Trademark Office. The USPTO has given the RENDLIZEP trademark a serial number of 79193210. The federal status of this trademark filing is CANCELLED - SECTION 71 as of Friday, March 1, 2024. This trademark is owned by CROSSJECT. The RENDLIZEP trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical products, namely, pharmaceutical preparations for the treatment of rheumatoid arthritis and autoimmune diseases
rendlizep

General Information

Serial Number79193210
Word MarkRENDLIZEP
Filing DateFriday, August 12, 2016
Status709 - CANCELLED - SECTION 71
Status DateFriday, March 1, 2024
Registration Number5262989
Registration DateTuesday, August 15, 2017
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 30, 2017

Trademark Statements

Goods and ServicesPharmaceutical products, namely, pharmaceutical preparations for the treatment of rheumatoid arthritis and autoimmune diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, March 1, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCROSSJECT
Party Type30 - Original Registrant
Legal Entity Type33 - NOT AVAILABLE
AddressFR
Party NameCROSSJECT
Party Type20 - Owner at Publication
Legal Entity Type33 - NOT AVAILABLE
AddressFR
Party NameCROSSJECT
Party Type10 - Original Applicant
Legal Entity Type33 - NOT AVAILABLE
AddressFR

Trademark Events

Event DateEvent Description
Friday, March 1, 2024CANCELLED SECTION 71
Monday, August 15, 2022COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Friday, December 22, 2017FINAL DECISION TRANSACTION PROCESSED BY IB
Tuesday, December 5, 2017FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, December 5, 2017FINAL DISPOSITION PROCESSED
Wednesday, November 15, 2017FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, August 15, 2017REGISTERED-PRINCIPAL REGISTER
Tuesday, May 30, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 30, 2017PUBLISHED FOR OPPOSITION
Wednesday, May 10, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, April 21, 2017LAW OFFICE PUBLICATION REVIEW COMPLETED
Thursday, April 6, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, March 27, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, March 27, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 22, 2017ASSIGNED TO LIE
Monday, March 6, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, November 18, 2016REFUSAL PROCESSED BY IB
Wednesday, November 2, 2016NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, November 2, 2016REFUSAL PROCESSED BY MPU
Tuesday, November 1, 2016NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, October 31, 2016NON-FINAL ACTION WRITTEN
Saturday, October 29, 2016ASSIGNED TO EXAMINER
Saturday, October 15, 2016APPLICATION FILING RECEIPT MAILED
Tuesday, October 11, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, October 6, 2016SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

rendlizep pharmaceutical arthritis autoimmune diseases rheumatoid treatment products namely preparations